The Food and Drug Administration has revoked the emergency use authorisation covering Comirnaty, the Pfizer and BioNTech COVID 19 vaccine, in children aged six months through four years. The revocation notice, published in the Federal Register on October 15, states that it was issued at the request of Pfizer and BioNTech and identifies no safety concern with the product.
Emergency use authorisations were the legal scaffolding of the pandemic response, allowing products to be used before full approval. Their revocation, years later and at the manufacturer’s own request, is the scaffolding coming down: the youngest children’s formulation never converted into a durable commercial market, and the companies chose to end the authorisation rather than maintain it.
The distinction matters for how the item travels. A revocation at request, documented in the government’s own register, is not a withdrawal for safety, and conflating the two is how administrative notices become misinformation. The commercial effect on either company is negligible; the documentary effect, closing a chapter of the emergency framework, is the news.